Minireview: The OPG/RANKL/RANK system

Endocrinology

Volumn 142, Issue 12, 2001, Pages 5050-5055

  Khosla, Sundeep ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN RANK; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; GENE EXPRESSION; GENE FUNCTION; MOLECULAR CLONING; MULTIGENE FAMILY; NONHUMAN; OSTEOCLAST; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SKELETON;

EID: 0035206443     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.12.8536     Document Type: Short Survey

References (56)

1. Evidence of estrogen receptors in normal human osteoblast-like cells
2. Estrogen binding receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells
3. A parathyroid hormone-related protein implicated in malignant hypercalcemia: Cloning and expression
4. Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy
5. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth
6. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation
7. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts
8. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis
9. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
10. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
11. Role of osteoblasts in hormonal control of bone resorption - A hypothesis
12. Osteoblastic cells are involved in osteoclast formation
13. Modulation of osteoclast differentiation
14. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
15. Characterization of structural domains of human osteoclastogenesis inhibitory factor
16. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
17. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
18. Osteoprotegerin is an α v β3-induced, NF-κB-dependent survival factor for endothelial cells
19. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
20. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
21. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells
22. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
23. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
24. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
25. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
26. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
27. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
28. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
29. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
30. Osteopetrosis in mice lacking NF-κB1 and NF-κB2
31. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: Regulation of mRNA expression of osteoclast differentiation factor (ODF)
32. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells
33. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
34. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells
35. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation
36. Promotor structure of mouse RANKL/TRANCE/OPGL/ODF gene
37. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
38. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
39. 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α
40. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization
41. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β
42. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression
43. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation
44. 1
45. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated
46. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
47. Immunological Characterization of Circulating Osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
48. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges
49. Glucocorticoid-induced osteoporosis: Pathogenesis and management
50. Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells
51. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone
52. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
53. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent
54. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
55. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy
56. The effect of a single dose of osteoprotegerin in postmenopausal women